|
Dr. Goldknopf has over 30 years of proteomic experience. He is a well recognized pioneer and leader in Proteomics, having produced, the first isolation, identification and sequencing of a new protein spot on a 2D gel. He also discovered ubiquitin conjugation of proteins, which laid the groundwork for the 2000 Lasker award. He was cofounder of ProteEx in 2000 and prior to that was founding CEO of UbiquiTex Technologies, and cofounder and VP of R&D of FlowGenix Corporation. His experience also includes Manager GMP, QC/QA, and analytical operations, GAF/ISP and Triplex Pharmaceuticals. He spent 10 years on the faculty of Baylor College of Medicine and a sabbatical year at the Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden. He is the author of more than 70 publications and also serves on the Scientific Advisory Board of the Company.
Dr. Goldknopf began his scientific career over 30 years ago, pioneering the field that is now known as Proteomics. More than a decade before the start of the Human Genome Project, Dr. Goldknopf made the earliest proteomic discovery at Baylor College of Medicine with Harris Busch, the isolation, identification, and sequencing of a new protein from a two-dimensional gel, Protein A24. During the course of these investigations, he discovered that protein A24 was the first known conjugate of two very important proteins, Histone H2A, a part of the subunit structure that packages DNA in the cell nucleus, and Ubiquitin. Through the work of Dr. Goldknopf and many others(>9000 publications in the ensuing years), including Drs. Avram Hershko, Aaron Ciechanover, and Alex Varshavsky, who shared the 2000 Lasker Award for their achievements, the Ubiquitin Conjugation System is now known to play a major role in the management of the inventories of proteins in the cell, cell proliferation, programmed cell death, and most if not all major regulatory functions in health and disease at the cellular level. Now equipped with a new perspective on the importance of commercializing products and with the benefit of a strong management team at Power3, Dr. Goldknopf continues to push the envelope of Proteomics through discovery of protein biomarkers and biomarker footprints for early detection, monitoring and drug targeting in patients with breast cancer, neurodegenerative diseases, and chemotherapeutic drug resistance. Dr. Goldknopf has presented his recent findings at the Human Proteome Meeting and the International Conference on Ubiquitin, Ubiquitin-Like Proteins, and Cancer in 2004. He is the author of more than 70 publications, book chapters, and patents. | 